Cargando…

Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland

INTRODUCTION: Currently, 15–20% of individuals with coronary artery disease (chronic coronary syndrome [CCS]) or peripheral artery disease (PAD) receiving routine treatment experience cardiovascular events (CVEs) within 3–4 years. Using PICOSTEPS (Patients-Intervention-Comparators-Outcomes-Setting-T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soini, Erkki, Virtanen, Outi, Väätäinen, Saku, Briere, Jean-Baptiste, Bowrin, Kevin, Millier, Aurelie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467417/ https://www.ncbi.nlm.nih.gov/pubmed/32519113 http://dx.doi.org/10.1007/s12325-020-01398-8

Ejemplares similares

Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease
por: Cowie, Martin R, et al.
Publicado: (2020)

Economic Value of Adjunctive Brivaracetam Treatment Strategy for Focal Onset Seizures in Finland
por: Väätäinen, Saku, et al.
Publicado: (2019)

Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials
por: Bauersachs, Rupert, et al.
Publicado: (2020)

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
por: Bowrin, Kevin, et al.
Publicado: (2020)

Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review
por: Bauersachs, Rupert, et al.
Publicado: (2019)

Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
por: Bowrin, Kevin, et al.
Publicado: (2020)

Antithrombotic treatment patterns in patients with atrial fibrillation in Italy pre- and post-DOACs: the REPAIR study
por: Esposti, Luca D, et al.
Publicado: (2019)

Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany
por: Theidel, Ulrike, et al.
Publicado: (2017)

Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation
por: Coleman, Craig I., et al.
Publicado: (2019)

Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain
por: Escobar Cervantes, Carlos, et al.
Publicado: (2022)

Cost–Utility of First-Line Actinic Keratosis Treatments in Finland
por: Soini, Erkki J., et al.
Publicado: (2015)

Assessment of the burden of disease for patients with peripheral artery disease undergoing revascularization in England
por: Portas, Laura, et al.
Publicado: (2022)

Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland
por: Hallinen, Taru, et al.
Publicado: (2023)

Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective
por: Levy, Pierre, et al.
Publicado: (2019)

Antithrombotic therapy in peripheral arterial disease
por: Espinola-Klein, Christine, et al.
Publicado: (2022)

Molecular Epidemiology of Tuberculosis in Finland, 2008-2011
por: Smit, Pieter Willem, et al.
Publicado: (2013)

Antithrombotic Treatment in Lower Extremity Peripheral Arterial Disease
por: Gottsäter, Anders
Publicado: (2021)

Tuberculosis screening of asylum seekers in Finland, 2015–2016
por: Räisänen, Pirre E., et al.
Publicado: (2020)

Lyme Borreliosis in Finland, 1995–2014
por: Sajanti, Eeva, et al.
Publicado: (2017)

Advantages in Management and Remote Monitoring of Intravenous Therapy: Exploratory Survey and Economic Evaluation of Gravity-Based Infusions in Finland
por: Puolitaival, Antti, et al.
Publicado: (2022)

Transmission of tuberculosis between foreign-born and Finnish-born populations in Finland, 2014–2017
por: Räisänen, Pirre Emilia, et al.
Publicado: (2021)

Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland
por: Soini, Erkki, et al.
Publicado: (2017)

Enhanced surveillance for tuberculosis among foreign-born persons, Finland, 2014–2016
por: Räisänen, Pirre E., et al.
Publicado: (2018)

Risk factors affecting treatment outcomes for pulmonary tuberculosis in Finland 2007–2014: a national cohort study
por: Korhonen, Virve, et al.
Publicado: (2020)

Primary-care-based episodes of care and their costs in a three-month follow-up in Finland
por: Heinonen, J., et al.
Publicado: (2015)

Antithrombotic therapy in coronary artery disease patients with atrial fibrillation
por: Wei, Lili, et al.
Publicado: (2020)

Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease
por: Moustafa, Abdelmoniem, et al.
Publicado: (2019)

Antithrombotic Therapy in Patients with Coronary Artery Disease and Prior Stroke
por: Bellettini, Elisa, et al.
Publicado: (2021)

Administration costs of intravenous biologic drugs for rheumatoid arthritis
por: Soini, Erkki J, et al.
Publicado: (2013)

Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions
por: Canonico, Mario Enrico, et al.
Publicado: (2023)

Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study
por: Hoogendoorn, Martine, et al.
Publicado: (2021)

Impact of Antithrombotic Therapy in Atrial Fibrillation on the Presentation of Coronary Artery Disease
por: Chan, Pak Hei, et al.
Publicado: (2015)

Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis
por: Bauersachs, Rupert, et al.
Publicado: (2021)

Burden and Prevention of Adverse Cardiac Events in Patients with Concomitant Chronic Heart Failure and Coronary Artery Disease: A Literature Review
por: Lavoie, Louis, et al.
Publicado: (2016)

The costs of offering HPV-testing on self-taken samples to non-attendees of cervical screening in Finland
por: Virtanen, Anni, et al.
Publicado: (2015)

The North Karelia Project: Cardiovascular disease prevention in Finland
por: Vartiainen, Erkki
Publicado: (2018)

Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis
por: Solo, Karla, et al.
Publicado: (2019)

Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation
por: Rivera-Caravaca, José Miguel, et al.
Publicado: (2021)

A Comparison of Lung Tumour Types in Finland and Norway
por: Kreyberg, Leiv, et al.
Publicado: (1961)

Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
por: Hallinen, Taru, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jrtao7ontgr0u5h2cqtspul108